Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPuS-2 prophylaxis trial of BCX4161 in hereditary angioedema
2014-002655-26Phase 3Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avoralstat in hereditary angioedema (HAE) (3 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Mean acute angioedema attack rate. Started Nov 2014; status: completed.
02
Drugs
avoralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2014-002655-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002655-26.